GLP-1 medications
Coverage of GLP-1 medications in the Nexus archive.
- Cancer doctor reveals 5 habits that may reduce disease risk and improve outcomes
A surgical oncologist revealed that simple lifestyle measures, such as maintaining a healthy weight and staying active, can help lower the risk of developing certain diseases and improve outcomes. Research also suggests that GLP-1 medications like Ozempic and Wegovy may be linked to a reduced cancer risk because they promote weight loss and reduce chronic inflammation.
- The hidden risk of GLP-1 drugs
GLP-1 drugs can cause weight loss, which results in an estimated 25% decline in musculoskeletal mass and increases the risk of fractures, especially for older adults. To mitigate this risk, patients should pair GLP-1 use with exercise and strength training while maintaining proper nutrition high in protein, calcium, vitamin D, and magnesium.
- Bank of America is spending $250 million a year on weight loss drugs for employees
Bank of America is allocating $250 million annually for weight loss drugs for employees. CEO Brian Moynihan reported that GLP-1 medications now make up approximately 13% of the company's total healthcare expenditures.
- Taking Weight-Loss Drugs Could Help Reduce Violent Impulses
A study by Rutgers University researchers suggests GLP-1 weight-loss drugs like Ozempic and Wegovy may reduce links between impulsivity, alcohol use, and violent behavior. The research found associations between impulsivity and violence were 62% weaker among current users compared to former users, while alcohol-related violence was 52% weaker.
- Health experts weigh benefits, costs as more Carolinians turn to GLP-1s for weight loss
GLP-1 medications, originally developed for diabetes, are increasingly used for weight loss in North Carolina. A Gallup poll reveals usage has risen from 3% to 11% of Americans since 2024.
- Why cutting GLP-1 benefits could be a costly mistake for companies
Employers are reducing coverage for GLP-1 medications like Ozempic and Wegovy to cut healthcare costs, but a study suggests this may backfire. Research from the National Bureau of Economic Research found GLP-1 treatments reduced long-term sick leave by 17.3% and generated $866 in annual productivity gains per worker in Denmark. However, U.S. employers face different healthcare systems and higher costs, complicating direct comparisons.
- Novo Nordisk sues Eli Lilly over ads comparing GLP-1 medications
Novo Nordisk is suing Eli Lilly over advertisements comparing GLP-1 medications. The drugmaker claims Lilly’s ads exclude the most up-to-date clinical information about its drugs.
- GLP-1 insurance change impacts millions of Americans: What to know, how to tell if you're covered
Insurance coverage for GLP-1 medications, popular for weight loss, has changed for up to 56 million Americans. The update affects how these medications are covered by insurers.
- GLP-1 insurance change impacts millions of Americans: What to know, how to tell if you’re covered
Insurance coverage for GLP-1 medications, used for weight loss, changed for up to 56 million Americans. The update affects access to these popular drugs.
- Cutting GLP-1 coverage may cost UVM Health more than it saves
UVM Health is considering eliminating GLP-1 medication coverage for weight management to save $19 million annually. The author argues this decision overlooks long-term healthcare cost savings from improved patient outcomes, such as reduced specialist visits and chronic disease risks.
- STAT+: Online GLP-1 prescriptions are often fast, easy — and low on clinical oversight
A secret shopper study revealed that telehealth sites prescribing GLP-1 medications for weight loss often operate with minimal clinical oversight, enabling fast and easy access to drugs like semaglutide and tirzepatide. The study, conducted by a Yale researcher and published in the Journal of the American Medical Association, highlights concerns about virtual care practices and the market for non-FDA-approved compounded versions due to shortages.
- Medicare pilot program expands access to Wegovy, Zepbound for some seniors
A Medicare pilot program expands access to GLP-1 weight-loss medications like Wegovy and Zepbound for some seniors, offering subsidies as high as $50 per month. The program, running through 2027, requires a BMI above 35 or specific weight-related conditions for eligibility, though 6 million Medicare Part D recipients who might otherwise qualify will remain excluded. Concerns persist about potential bone and muscle density loss from rapid weight loss, but medical professionals suggest exercise can mitigate risks.
- Disposal of GLP-1 injection pens raises questions as use surges across the U.S.
Experts in Charlotte, N.C., are raising concerns about the disposal of GLP-1 injection pens as the use of weight-loss drugs like Ozempic, Wegovy, and Zepbound surges. Studies estimate roughly 12% of U.S. adults are using these medications, prompting questions about post-use waste management.
- Can GLP-1s boost testosterone levels?
A preliminary study found that testosterone levels increase or stabilize in people taking GLP-1 medications. The research suggests a potential link between GLP-1 use and improved testosterone levels.
- What to know about the temporary Medicare GLP-1 Bridge program
Starting in July, Medicare beneficiaries can access GLP-1 medications via a temporary program with a flat monthly fee. The program, set to run until 2027, faces operational uncertainties ahead of its launch.
- Popular weight-loss drugs linked to unexpected male fertility benefit
GLP-1 weight-loss drugs may improve male fertility by enhancing testosterone levels and semen quality in obese men with low testosterone. A review of five trials found no suppression of male reproductive hormones and potential benefits for metabolic health, though more research is needed.
- Could drugs like Ozempic make people less violent — and even reduce crime?
A new study suggests GLP-1 medications like Ozempic and Mounjaro may reduce the likelihood of violent behavior, potentially influencing broader decision-making beyond dietary choices.
- Ozempic users may be making a major weight-loss mistake, new study suggests
A new study suggests that adults taking GLP-1 medications like Ozempic or Wegovy for weight loss are significantly reducing their physical activity, with decreases in daily steps and moderate-to-vigorous exercise. Researchers emphasize that exercise remains essential for preserving strength and long-term health when using these drugs, despite the observed decline in activity.
- Doctor explains study showing GLP-1s may lower breast cancer risk
A study of over 111,000 women aged 45 to 80 found that those using GLP-1 medications had a 30% reduced risk of developing breast cancer.
- What Ozempic is actually doing to obesity rates in the US
GLP-1 medications like Ozempic are gaining popularity and significantly impacting the health landscape in the US, influencing obesity rates.
- Lilly’s GLP-1 medications will soon be covered by CVS, potentially opening access for millions of Americans
CVS will cover Lilly’s GLP-1 medications, Foundayo (a pill) and Zepbound (an injection), potentially expanding access for millions of Americans.
- 'Ozempic breath' sparks questions as users report strange side effect
Users of GLP-1 medications like Ozempic and Wegovy report a side effect called 'Ozempic breath,' characterized by a fishy or sewage-like odor. While not listed in official side effects, social media discussions and anecdotal evidence suggest dehydration, gut flora imbalance, and gastric reflux may contribute. Doctors recommend hydration, probiotics, and dietary changes to mitigate the issue.
- Why obesity drugs work better for some people: these genes hold clues
A study of nearly 28,000 people reveals genetic factors influencing the effectiveness of obesity drugs and their gastrointestinal side effects. Researchers identified specific genetic variants linked to varying responses to GLP-1 medications.